A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 6|浏览73

暂无评分

摘要

While antitumor activity was observed with molibresib, use was limited by gastrointestinal and thrombocytopenia toxicities. Investigations of molibresib as part of combination regimens may be warranted.

查看译文

关键词

molibresib,hematologic malignancies,treatment,open-label

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要